H.C. Wainwright Reiterates Buy Rating on Lisata Therapeutics, Inc (LSTA)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $15.00 price target on Lisata Therapeutics, Inc (NASDAQ: LSTA).

The analyst commented: "Yesterday, Lisata announced plans to expand on its existing strategic collaboration with GATC Health Corp. (private), a tech-bio company leveraging A.I. to drive drug discovery and development. The collaboration builds on the prior work performed by GATC for Lisata, which included utilization of GATC's MAT A.I. platform to analyze certepetide and identify optimized and de-risked development opportunities across various indications. GATC’s MAT A.I. simulates billions of complex systems biological interactions, predicting safety, efficacy, off-target effects, and clinical trial outcomes. Based on the outcome of GATC’s analysis, Lisata plans to optimize its Phase 3 development of certepetide in mPDAC while also identifying new indications with a high probability of development success. As part of the next step in the expansion of the collaboration, GATC's MAT A.I. platform will identify drugs that could be used in combination with certepetide across a range of indications, including those outside of oncology. As a last part of the partnership, and pertinent to yesterday's announcement, GATC will engage Lisata as an operational partner for the development of GATC's own drug development candidates, which includes targets for opioid addiction, PTSD, diabetes, obesity, GBM, and cognitive design. The collaboration has now identified the first development program for advancement, which will be a therapeutic agent targeting opioid use disorder (OUD). Discovered by GATC's MAT A.I. platform, the OUD candidate is a non-opioid small molecule new chemical entity for which preclinical studies have demonstrated a significant reduction in fentanyl intake in validated murine models. GATC’s OUD asset is targeted to enter Phase 1 human trials in 1H26, confirming Lisata’s ability to accelerate and optimize the overall development and regulatory process. Reiterate Buy rating and $15 PT."

For an analyst ratings summary and ratings history on Lisata Therapeutics, Inc click here. For more ratings news on Lisata Therapeutics, Inc click here.

Shares of Lisata Therapeutics, Inc closed at $2.40 yesterday.

You May Also Be Interested In

• Summitt Midstream Corp. (SMC) PT Raised to $43 at TD Cowen
• Compass Point Reiterates Buy Rating on CoreWeave (CRWV)
• BridgeBio Pharma (BBIO) PT Raised to $106 at Canaccord